Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.71 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.58 |
| ▸ | MET | P08581 | 16/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992230 | 0.89 | MET (0.67) | EGFRPDPK1CDK1CDK2MKNK1 | |
| SCHEMBL2681319 | 0.87 | FGFR1 (0.57) | EGFRMETFGFR1FGFR2FGFR3 | |
| SCHEMBL2681566 | 0.84 | MET (0.58) | EGFRPDPK1CDK1CDK2MKNK1 | |
| SCHEMBL2680942 | 0.84 | CDK1 (0.70) | EGFRPDPK1CDK1CDK2MKNK1 | |
| SCHEMBL4040666 | 0.83 | EGFR (1.00) | EGFRFGFR1FGFR2FGFR3 | |
| SCHEMBL16390864 | 0.83 | EGFR (0.51) | EGFRPDPK1CDK1CDK2MKNK1 | |
| SCHEMBL2681930 | 0.80 | EGFR (0.48) | EGFRMETFGFR1FGFR2FGFR3 | |
| SCHEMBL2384821 | 0.80 | MET (0.57) | EGFRMETKCNH2FGFR1FGFR2 | |
| SCHEMBL2385279 | 0.80 | MET (0.80) | METKCNH2 | |
| SCHEMBL16404816 | 0.79 | MET (0.51) | EGFRMETFGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | PDK1, PDK2, PDK4 | EGFR 2015/4885PDPK1 14/4885CDK1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.